Diazyme, San Diego, is partnering with Maccura Biotechnology USA, Rockville, Md, to launch an FDA EUA approved SARS-CoV-2 RT-PCR diagnostics test. “Here at Diazyme, we continue to address gaps in testing during the COVID-19 public health emergency,” says Chong Yuan, PhD, managing director of Diazyme Laboratories. “The SARS-CoV-2 Fluorescent PCR Kit- Maccura Biotechnology is a RT-PCR test intended for the qualitative detection of SARS-CoV-2 viral nucleic acids in upper respiratory specimens (for example, oropharyngeal swabs, nasopharyngeal swabs, nasal swabs, and mid-turbinate swabs) from individuals suspected of covid-19. The demand for molecular diagnostic tests continues to outpace availability and wait times are getting too long to be meaningful in quarantine situations. We are pleased to announce our partnership with Maccura, bringing more test capacity to clinical laboratories.” “Maccura Biotechnology (USA) is pleased to enter into a partnership with Diazyme Laboratories, providing additional testing capacity during the public health emergency in the USA,” says Jinson Xu, the general manager of Maccura Biotechnology (USA). “We have a long business relationship with Diazyme and continue to work together in many areas globally.” For more information, visit Diazyme.